BSEConcord Drugs LtdLowNeutral
Announced Wed, 1 Oct · 16:12 IST

Voting results and Scrutinizers Report

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Concord Drugs Ltd held its 30th Annual General Meeting on September 30, 2025, via Video Conference from 9:30 a.m. to 9:54 a.m. A total of 9 resolutions were put to vote and all were passed with overwhelming shareholder support — over 99.99% in favor on each resolution. The resolutions included adoption of audited financial statements, re-appointment of directors (Mr. S. Nagi Reddy as Chairman & MD, Mr. S. Koni Reddy and Mr. S. Manoj Kumar Reddy as Wholetime Directors), appointment of Mr. Satyam Reddy Gopidi as a Non-Executive Independent Director, approval of related party transactions for FY 2025-26, ratification of cost auditor remuneration, and appointment of PSK & Associates as secretarial auditors. The promoter group (54,39,204 shares) voted 100% in favor on all resolutions. Public shareholder participation was very low — only 8,912 out of 45,60,796 public shares (0.1954%) were polled.

Likely market impact

This is a routine procedural disclosure — all standard AGM business was cleared without any pushback from shareholders. No major strategic shift or capital event was announced. The very low public voting turnout (0.2%) is a notable governance flag, though all items passed comfortably.